Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Improving practice and knowledge around the field of anticoagulation reversal is vital to appropriate care of patients. Pharmacists are in a critical role to help other health care professionals analyze and evaluate the appropriateness or necessity of bleeding reversal. This activity will include an overview of the types of major bleeding and available reversal agents along with treatment options. Discussion of procurement and availability will also be included.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Katelyn W. Sylvester, PharmD, CACP, BCPS
Pharmacy Manager – Anticoagulation Services
Department of Pharmacy
Brigham and Women’s Hospital
Release Date: 06-27-2019
Expiration Date: 07-31-2020
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-195-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Sylvester
has participated on a scientific advisory board for Bristol Myers Squibb/Pfizer and
acted as consultant for Portola Pharmaceuticals, Inc. There will be off-label and/or
Please note: The opinions expressed in this activity should not be construed as those of the CE provider or Portola Pharmaceuticals, Inc. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.